|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alzahrani AS and Xing M: Impact of Iymph
node metastases identified on central neck dissection (CND) on the
recurrence of papillary thyroid cancer: Potential role of BRAFV600E
mutation in defining CND. Endocr Relat Cancer. 20:13–22. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shen X, Liu R and Xing M: A Six-genotype
genetic prognostic model for papillary thyroid cancer. Endocr Relat
Cancer. 24:41–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xing M: BRAF mutation in thyroid cancer.
Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li C, Lee KC, Schneider EB and Zeiger MA:
BRAF V600E mutation and its association with clinicopathological
features of papillary thyroid cancer: A meta-analysis. J Clin
Endocrinol Metab. 97:4559–4570. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elisei R, Ugolini C, Viola D, Lupi C,
Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A and Basolo F:
BRAF (V600E) mutation and outcome of patients with papillary
thyroid carcinoma: A 15-year median follow-up study. J Clin
Endocrinol Metab. 93:3943–3949. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK,
Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, et al: The association of
the BRAF(V600E) mutation with prognostic factors and poor clinical
outcome in papillary thyroid cancer: A meta-analysis. Cancer.
118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amin MB: AJCC Cancer Staging Manual. 8th.
Springer; New York, NY: 2017, View Article : Google Scholar
|
|
11
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association Management
Guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid Association
Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid
Cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takacsova E, Kralik R, Waczulikova I,
Zavodna K and Kausitz J: A different prognostic value of BRAFV600E
mutation positivity in different age groups of patients with
papillary thyroid cancer. Neoplasma. 64:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The Cancer Genome Atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
14
|
Eisen MB, Spellman PT, Brown PO and
Botstein D: Cluster analysis and display of genome-wide expression
patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Omry-Orbach G: Risk stratification in
differentiated thyroid cancer: An ongoing process. Rambam
Maimonides Med. 72016.
|
|
16
|
Luster M, Clarke SE, Dietlein M, Lassmann
M, Lind P, Oyen WJ, Tennvall J and Bombardieri E; European
Association of Nuclear Medicine (EANM), : Guidelines for
radioiodine therapy of differentiated thyroid cancer. Eur J Nucl
Med Mol Imaging. 35:1941–1959. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G,
Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: Genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 63:1454–1457. 2003.PubMed/NCBI
|
|
19
|
Xing M: BRAF mutation in papillary thyroid
cancer: Pathogenic role, molecular bases, and clinical
implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen X, Zhu G, Liu R, Viola D, Elisei R,
Puxeddu E, Fugazzola L, Colombo C, Jarzab B, Czarniecka A, et al:
Patient age-associated mortality risk is differentiated by BRAF
V600E status in papillary thyroid cancer. J Clin Oncol. 36:438–445.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haymart MR: Understanding the relationship
between age and thyroid cancer. Oncologist. 14:216–221. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sumimoto H, Imabayashi F, Iwata T and
Kawakami Y: The BRAF-MAPK signaling pathway is essential for
cancer-immune evasion in human melanoma cells. J Exp Med.
203:1651–1656. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Angell TE, Lechner MG, Jang JK, Correa AJ,
LoPresti JS and Epstein AL: BRAF V600E in papillary thyroid
carcinoma is associated with increased programmed death ligand 1
expression and suppressive immune cell infiltration. Thyroid.
24:1385–1393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim H, Kim TH, Choe JH, Kim JH, Kim JS, Oh
YL, Hahn SY, Shin JH, Chi SA, Jung SH, et al: Patterns of initial
recurrence in completely resected papillary thyroid carcinoma.
Thyroid. 27:908–914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suh YJ, Kwon H, Kim SJ, Choi JY, Lee KE,
Park YJ, Park DJ and Youn YK: Factors affecting the locoregional
recurrence of conventional papillary thyroid carcinoma after
surgery: A retrospective analysis of 3381 patients. Ann Surg Oncol.
22:3543–3549. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xing M: Prognostic utility of BRAF
mutation in papillary thyroid cancer. Mol Cell Endocrinol.
321:86–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Durante C, Puxeddu E, Ferretti E, Morisi
R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A,
et al: BRAF mutations in papillary thyroid carcinomas inhibit genes
involved in iodine metabolism. J Clin Endocrinol Metab.
92:2840–2843. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zoghlami A, Roussel F, Sabourin JC, Kuhn
JM, Marie JP, Dehesdin D and Choussy O: BRAF mutation in papillary
thyroid carcinoma: Predictive value for long-term prognosis and
radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis.
131:7–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
